Clinical, Electrocardiographic, and Cardiac Magnetic Resonance Imaging Risk Factors Associated with Ventricular Tachyarrhythmias in Nonischemic Cardiomyopathy (MARVEN Study)
The specific aims of the trial are to prospectively study nonischemic cardiomyopathy patients qualified for CRT-D following currently approved standard indications in order to: 1) Validate the MADIT-CRT-derived model predicting fast VT/VF in nonischemic cardiomyopathy patients with QRS≥120 ms. 2) Determine whether CMR added to the risk model validated in specific aim 1 will further improve risk stratification for predicting fast VT/VF in nonischemic cardiomyopathy patients with QRS≥120ms. 3) Evaluate costs of risk stratification using Holter and CMR in relationship to costs of implanted devices without risk stratification.
• At least 21 years of age
• Diagnosed with nonischemic dilated cardiomyopathy (NICM)
• On optimal medications for management
• If a cardiac defibrillator hasn't been implanted, must be willing to have a cardiac defibrillator implanted within 3 months of study enrollment
• If a cardiac defibrillator has been implanted, it must be more recent than July 1, 2018
• Nonischemic cardiomyopathy due to other known causes such as amyloidosis, sarcoidosis, cardiotoxicity due to chemotherapy, hypertrophic cardiomyopathy,
• History of prior myocardial infarction, percutaneous coronary intervention, or coronary bypass grafting
• History of ablation to treat ventricular fibrillation
Heart & Vascular
Clinics and Surgery Center (CSC), Implantable cardioverter defibrillator (ICD), Nonischemic dilated cardiomyopathy (NICM)